STOCK TITAN

Korsana Biosciences: ADAR1 reports 0.1% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Korsana Biosciences, Inc. (KRSA) is the issuer in an amended report by ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager, who report beneficial ownership of 43,574 common shares. The shares are owned directly by private investment funds managed by ADAR1; the reporting persons report shared voting and dispositive power. The position represents 0.1% of the class, based on 45,541,358 shares outstanding as of September 30, 2026, after giving effect to the 1-for-7 reverse stock split and merger effected September 8, 2026.

Shares beneficially owned 43,574 shares Reported by ADAR1 Capital Management, LLC and Daniel Schneeberger
Percent of class 0.1% Based on shares outstanding as of September 30, 2026
Shares outstanding 45,541,358 shares As of September 30, 2026, after giving effect to the reverse stock split and merger
Reverse stock split 1-for-7 Effected September 8, 2026
beneficially owned regulatory
"43,574 shares ... may be deemed to be indirectly beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 43,574.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 43,574.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KRSA shares do ADAR1 Capital Management and Daniel Schneeberger report owning?

ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of 43,574 KRSA common shares, or 0.1% of the class. The shares are held directly by private investment funds managed by ADAR1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





23255M303

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 43,574 shares of common stock, no par value ("Common Stock"), of Korsana Biosciences, Inc. (formerly known as Cyclerion Therapeutics, Inc.) (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 45,541,358 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026, after giving effect to the 1-for-7 reverse stock split and the merger effected on September 8, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 11, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 43,574 shares of common stock, no par value ("Common Stock"), of Korsana Biosciences, Inc. (formerly known as Cyclerion Therapeutics, Inc.) (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 45,541,358 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026, after giving effect to the 1-for-7 reverse stock split and the merger effected on September 8, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 11, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026

Keep reading